Skip to main content
Industry News
FDA OKs sNDA for bupivacaine liposome injectable
3/24/2021

The FDA approved Pacira BioSciences' supplemental new drug application to expand the indication of Exparel, its injectable bupivacaine liposome suspension treatment to cover pediatric patients aged 6 years and older. The drug is used for post-surgical non-opioid pain control.

Full Story: